Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring.
Seguro FS, Silva CMPDC, Moura CMB, Conchon M, Fogliatto L, Funke VAM, Abdo A, Macedo AVS, Santos MHHD, Saraiva JFK. Seguro FS, et al. Hematol Transfus Cell Ther. 2021 Apr-Jun;43(2):191-200. doi: 10.1016/j.htct.2020.04.009. Epub 2020 Jul 1. Hematol Transfus Cell Ther. 2021. PMID: 32631809 Free PMC article. Review.
COVID-19 in chronic myeloid leukemia patients in Latin America.
Pagnano KB, Peralta EH, Navarro JR, David Salas LDR, Delgado N, Moiraghi B, Toreli ACM, Perobelli LM, Fechio L, Quixada ATS, Funke V, Bendit I, Seguro FS, Pilleux L, Bortolini J, Lourenço ALG, Sapelli J, Nucci FM, Pavlovsky C, Oliveira LDC, Moura MS, Palma LC, Gonçalves NN, Conchon M, Hokama POM, Almeida LL, Zulli R, de Souza CA, Boquimpani CM. Pagnano KB, et al. Among authors: seguro fs. Leuk Lymphoma. 2021 Dec;62(13):3212-3218. doi: 10.1080/10428194.2021.1950709. Epub 2021 Jul 13. Leuk Lymphoma. 2021. PMID: 34254886
Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.
Boquimpani C, Seguro FS, Magalhães GHR, Pinto ILS, Bendit I, Bortolini JAP, Pagnano KBB, Centrone R, Funke V. Boquimpani C, et al. Among authors: seguro fs. Hematol Transfus Cell Ther. 2022 Jul-Sep;44(3):402-409. doi: 10.1016/j.htct.2022.04.002. Epub 2022 May 3. Hematol Transfus Cell Ther. 2022. PMID: 35654721 Free PMC article. Review.
Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel.
Velloso EDRP, Padulla GA, de Cerqueira AMM, de Sousa AM, Sandes AF, Traina F, Seguro FS, Nogueira FL, Pereira GF, Boechat JL, Pagnano KBB, Marchi LL, Ensina LF, Giavina-Bianchi M, Aun MV, Agondi RC, Santos FPS, Giavina-Bianchi P. Velloso EDRP, et al. Among authors: seguro fs. Hematol Transfus Cell Ther. 2022 Oct-Dec;44(4):582-594. doi: 10.1016/j.htct.2022.04.006. Epub 2022 May 26. Hematol Transfus Cell Ther. 2022. PMID: 35688791 Free PMC article.
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I. Ferreira APS, et al. Among authors: seguro fs. Ann Hematol. 2023 Jul;102(7):1761-1771. doi: 10.1007/s00277-023-05189-3. Epub 2023 Apr 13. Ann Hematol. 2023. PMID: 37052662 Free PMC article.
Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response.
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I. Ferreira APS, et al. Among authors: seguro fs. Ann Hematol. 2023 Jul;102(7):1969. doi: 10.1007/s00277-023-05242-1. Ann Hematol. 2023. PMID: 37160499 Free PMC article. No abstract available.
22 results